NCT04328844 2026-03-30A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic CancersiOncturaPhase 1 Active not recruiting210 enrolled
NCT03636503 2025-02-06Rituximab + Immunotherapy in Follicular LymphomaDana-Farber Cancer InstitutePhase 1 Terminated24 enrolled 25 charts